Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

Rhea-AI Summary

Oragenics (NYSE American: OGEN), a biotech company focused on intranasal therapeutics for brain-related conditions, announces its participation in two major industry events in June 2025. Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention in Boston (June 16-19), where he will discuss ONP-002, the company's lead intranasal neurosteroid candidate for treating concussion. Additionally, Oragenics will attend the 42nd Annual National Neurotrauma Society Symposium in Philadelphia (June 15-18), co-hosted by the National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care. These events provide platforms for Oragenics to showcase its development pipeline and engage with industry leaders in neuroscience, neurology, biotech, and pharma.

News Market Reaction – OGEN

+4.16%

+4.16% Session move

In the trading session that priced this news, OGEN gained 4.16%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced that Greg Gironda, Head of Business Development, will present at the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. In addition, Oragenics will also attend the 42nd Annual National Neurotrauma Society (NNS) Symposium, being held June 15–18, 2025, in Philadelphia, Pennsylvania.

These back-to-back events represent key opportunities for Oragenics to highlight its lead candidate, ONP-002, an intranasal neurosteroid in development for the treatment of concussion (mild traumatic brain injury), and to engage with global leaders in neuroscience, neurology, biotech, and pharma.

2025 BIO International Convention

• Dates: June 16–19, 2025
  
• Location: Boston Convention & Exhibition Center, Boston, MA
  
• Presentation Date & Time: June 19, 2025, from 11:30 AM – 11:45 AM ET
  
• Registration: https://www.bio.org/events/bio-international-convention/registration
  

42nd Annual National Neurotrauma Society (NNS) Symposium

• Dates: June 15–18, 2025
  
• Location: Philadelphia Marriott Downtown, Philadelphia, PA
  
• Co-hosts: National Neurotrauma Society and AANS/CNS Joint Section on Neurotrauma & Critical Care
  

About Oragenics, Inc.
Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company’s intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit www.oragenics.com.

Investor Contact:
Rich Cockrell
CG Capital
866.889.1972
ogen@cg.capital

FAQ

When and where will Oragenics (OGEN) present at the 2025 BIO International Convention?

Oragenics will present on June 19, 2025, from 11:30 AM to 11:45 AM ET at the Boston Convention & Exhibition Center in Boston, MA.

What is Oragenics' (OGEN) lead drug candidate ONP-002?

ONP-002 is an intranasal neurosteroid being developed for the treatment of concussion (mild traumatic brain injury).

Which two major industry events will Oragenics (OGEN) attend in June 2025?

Oragenics will attend the 2025 BIO International Convention in Boston (June 16-19) and the 42nd Annual National Neurotrauma Society Symposium in Philadelphia (June 15-18).

Who will represent Oragenics (OGEN) at the 2025 BIO International Convention?

Greg Gironda, Head of Business Development at Oragenics, will present at the convention.